Financial Performance - Apellis reported approximately $151 million in GA (Geographic Atrophy) revenue for 2Q 2025[10] - EMPAVELI U S net product sales were $208 million in 2Q 2025[18] - SYFOVRE U S net product sales were $1506 million in 2Q 2025[18] - The company received $275 million upfront from a royalty purchase agreement for 90% of future ex-U S royalties for Aspaveli[17] - Total revenue for 2Q 2025 was $1785 million, compared to $1997 million in 2Q 2024[18] EMPAVELI and Pipeline - EMPAVELI received U S FDA approval for C3G and primary IC-MPGN[10] - Apellis plans to initiate pivotal studies in DGF (Delayed Graft Function) and FSGS (Focal Segmental Glomerulosclerosis) by year end[10, 21] - APL-3007 reduced circulating C3 concentration by up to 90% in a Phase 1 healthy volunteer study[25] SYFOVRE - SYFOVRE's overall GA market share exceeds 60%[10] - Apellis initiated a Phase 2 study of SYFOVRE + APL-3007[10, 23] Market and Strategy - Approximately 5,000 C3G and primary IC-MPGN patients are estimated in the U S [28, 29] - The company aims to raise awareness about EMPAVELI as a disease-modifying therapy and establish it as the treatment of choice for relevant conditions[33, 34]

Financial Performance & Guidance - Allegro's 1QFY26 net sales reached $203 million, exceeding the high end of guidance[10] - The gross margin for 1QFY26 was 48.2%, surpassing the guidance and showing a 260 bps quarter-over-quarter improvement[10, 14] - EPS for 1QFY26 was $0.09, above the midpoint of guidance[10, 14] - Free cash flow for 1QFY26 was $51 million, representing 25% of sales[14] - The company made $35 million in voluntary debt repayments during the quarter[14] - 2QFY26 sales guidance is between $205 million and $215 million, implying 12% year-over-year growth[19] - 2QFY26 gross margin is expected to be between 48% and 50%, and EPS between $0.10 and $0.14[19] Business Growth & Strategy - Net sales increased 22% year-over-year[15] - Auto sales increased 13% year-over-year, driven by e-Mobility which grew 31% year-over-year[15] - Industrial and Other sales increased 50% year-over-year, with strength in Data Center and Robotics & Automation[15] - 75% of design wins were in strategic focus areas, including xEV traction inverters and ADAS/EV applications[15]

Financial Performance - Revenues for Q2 2025 reached $2.0 billion, a 6% increase year-over-year[14] - Adjusted EBITDA for Q2 2025 was $242 million, up 12% year-over-year[15] - Adjusted EBITDA margin expanded by 70 bps to 12.4%[16] - Year-to-date operating cash flow increased by 20%[46] - The company's net debt is $2.234 billion, with a net debt to TTM Adjusted EBITDA ratio of 2.4x[55] Backlog and Contract Wins - Total Backlog & Options stand at $21.6 billion[19] - The TTM Book-to-Bill ratio is 1.0x[19] - QTD Book-to-Bill ratio is 0.9x[19] - Mission Tech backlog & options is $17.8 billion[24] - Sustainable Tech backlog is $3.7 billion[24] Future Outlook - FY25 Revenues guidance is revised to $7.9 billion - $8.1 billion[56]

Financial Performance Highlights - Second quarter 2025 revenue reached $272 million, a 41% increase driven by growth in Aviation distribution and MRO businesses, as well as contributions from recent acquisitions[11] - Adjusted EBITDA for the second quarter 2025 was $43 million, representing 16% of revenue, a 52% increase due to distribution program execution, increased MRO activity, strong OEM licensed manufacturing program performance, and acquisitions[11] - Adjusted Net Income for the second quarter 2025 was $20 million, and Adjusted diluted earnings per share was $0.97, representing increases of 149% and 106% respectively[11] Business Developments - The company completed the sale of the Fleet segment, repositioning itself as a pure-play Aviation Aftermarket business[6] - Turbine Weld Industries ("Turbine Weld") was acquired, expanding MRO engine component capabilities[6] - A new 5-year authorized services center agreement was signed with Eaton to support aftermarket MRO for Eaton hydraulics across the Americas[6] Balance Sheet and Capital Structure - Adjusted Net Leverage was 2.2x, including the Fleet sale and acquisition of Turbine Weld[11, 23] - Net Debt outstanding was $362 million, while cash and revolver availability was $333 million[23] - Second quarter 2025 Free Cash Flow was $6 million, driven by disciplined working capital management and record profitability[23] FY 2025 Guidance - Revenue Guidance: Reaffirming 35% to 40% year-over-year growth[20] - Aviation Adjusted EBITDA Margin Guidance: Increasing to 16.5% to 17%, the high-end of previously provided range[20]

July 31, 2025 1 CAUTIONARY STATEMENT REGARDING FORWARD LOOKING STATEMENTS 2Q25 Earnings Supplement This presentation may contain "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements regarding ICE's business that are not historical facts are forward- looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Although we believe the expectations reflected in these forward-looking st ...

Financial Performance - Q2 2025 - Revenue reached $135.1 million, a 6.5% increase year-over-year (YoY)[16, 17] - Non-GAAP EPS increased to $0.41, a 10.3% rise YoY[19, 20] - Revenue fulfilled through the Protolabs Network increased by 16% YoY in constant currencies, reaching $29.3 million[21] - Revenue increased 7% sequentially from Q1 2025[21] Revenue by Service - Q2 2025 (YoY in constant currencies) - Injection Molding revenue decreased by 4% to $47.4 million[23] - 3D Printing revenue decreased by 1% to $21.2 million[24] - Sheet Metal revenue increased by 9% to $4.3 million[25] - CNC Machining revenue increased by 20% to $61.9 million[27] Q3 2025 Outlook - Revenue is projected to be between $130 million and $138 million[33] - Non-GAAP EPS is expected to be in the range of $0.35 to $0.43[33] - Foreign currency is expected to have an approximately $0.4 million favorable impact on Q3 2025 revenue[35] Additional Metrics - Customer contacts using combined offer in LTM up nearly 45% YoY[5] - Revenue per customer contact in Q2 2025 grew 11% YoY[5] - 100% of Fortune 500 Companies Served in Aerospace + Defense[9]

Financial Performance - Q2 2025 sales reached $1.14 billion, a 4% year-over-year increase[4] - Adjusted EBITDA for Q2 2025 was $208 million, up 14% year-over-year, with a margin of 18.2%, a 150 bps increase[4] - Adjusted EPS for Q2 2025 was $0.74, compared to $0.60 in Q2 2024[4, 5] - Adjusted Free Cash Flow was $93 million, a 94% year-over-year increase[6] Segment Performance (Aerospace & Defense) - Aerospace & Defense (A&D) accounted for 67% of total sales, with $762 million in Q2[10, 11] - Commercial Jet Engines saw a 27% year-over-year growth in Q2 and 31% year-to-date, with expected growth exceeding 20% for 2025[10, 13] - HPMC (High Performance Materials & Components) segment margin was 23.7% in Q2, up 350 bps year-over-year[10] - AA&S (Advanced Alloys & Solutions) segment margin was 14.4%, a sequential dip due to defense, airframe, and energy timing[10] Outlook and Capital Allocation - The company expects an Adjusted EBITDA between $810 million and $840 million for the full year 2025[20] - The company expects an Adjusted EPS between $2.90 and $3.07 for the full year 2025[20] - The company expects a Free Cash Flow between $270 million and $350 million for the full year 2025[20] - $250 million in share repurchases were made in Q2, with over $800 million repurchased since 2022 at an average price of ~$48 per share[10]

Portfolio Performance - Total portfolio coverage increased to 2.1x in TTM June 2025, compared to 1.9x in YE 2019 [11] - The experiential portfolio consists of 274 properties with 52 operators, representing approximately $6.5 billion (94%) of total investments, and is 99% leased or operated [12] - The education portfolio consists of 55 properties with 5 operators and is 100% leased [12] - Total investments across 329 properties are approximately $6.9 billion, with 99% leased or operated [15] Box Office and Experiential Updates - First half of 2025 box office was $4.1 billion, a 15% increase over 2024, confirming 2025 estimates of $9.3 billion to $9.7 billion [19] - Q2 2025 box office was $2.7 billion, up 37% compared to 2024 [19] Investment and Capital Recycling - Q2 2025 investment spending was $48.6 million, bringing the year-to-date total to $86.3 million [15, 28] - 2025 investment spending guidance remains between $200 million and $300 million [29] - Revised 2025 disposition proceeds guidance is $130 million to $145 million, up from the prior guidance of $80 million to $120 million [34, 48] - Total proceeds from property sales were $35.6 million, with a net gain of $16.8 million [34] Financial Highlights - Total revenue for the quarter ended June 30, 2025, was $178.1 million, a 2.9% increase compared to $173.1 million in 2024 [38] - Net income attributable to common shareholders for the quarter was $69.6 million, a 78.0% increase compared to $39.1 million in 2024 [38] - Total revenue for the six months ended June 30, 2025, was $353.1 million, a 3.8% increase compared to $340.3 million in 2024 [41] - Net income attributable to common shareholders for the six months was $129.4 million, a 35.2% increase compared to $95.7 million in 2024 [41]

Q2 2025 Financial Performance - Revenue reached $1.1 billion, a 21% year-over-year increase[6] - Bookings totaled $1.4 billion, demonstrating a 51% year-over-year growth[6] - Average Daily Active Users (DAUs) grew to 111.8 million, up 41% year-over-year[6] - Hours Engaged increased to 27.4 billion, a 58% year-over-year rise[6] - Net loss was $(280) million[8] - Net cash provided by operating activities was $199 million, a 32% year-over-year increase[8] - Free cash flow was $177 million, a 58% year-over-year increase[8] Q3 and Fiscal Year 2025 Guidance - Q3 2025 revenue is projected between $1.11 billion and $1.16 billion, representing a 21% to 26% year-over-year increase[63] - Q3 2025 bookings are expected to range from $1.59 billion to $1.64 billion, indicating a 41% to 45% year-over-year growth[63] - Full year 2025 revenue is forecasted between $4.39 billion and $4.49 billion, a 22% to 25% year-over-year increase[64] - Full year 2025 bookings are projected between $5.87 billion and $5.97 billion, reflecting a 34% to 37% year-over-year growth[64]

Financial Performance - Total Q2 Revenue reached $63.2 million[6], with MACI contributing $53.5 million[6], Epicel $8.6 million[6], and NexoBrid $1.2 million[6] - MACI revenue experienced a growth of 21% reaching $53.5 million[10] - Gross margin increased to 74%, up over 400 bps compared to Q2 2024[10] - Adjusted EBITDA increased by 112% to $13.4 million[10] - The company holds $164 million in cash and investments[10] Business Highlights - Approximately 600 surgeons have been trained on MACI Arthro to date[10] - MACI implants for small femoral condyle defects increased by more than 40% in Q2 compared to the prior year[10] - NexoBrid second quarter revenue increased 52% vs prior year[10] - The company received FDA IND clearance for the MACI Ankle clinical study and remains on track to initiate the study in 2H 2025[10] MACI Arthro Launch - MACI Arthro trained surgeons continue to demonstrate expanded MACI utilization[14] - MACI implants for trochlea defects account for nearly 20% of MACI Arthro implants to date[14]